Climb Bio (CLYM) Cash from Financing Activities (2020 - 2026)

Climb Bio (CLYM) has 6 years of Cash from Financing Activities data on file, last reported at $5000.0 in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (down 100.01% YoY) and the FY2025 annual result came in at -$21000.0, down 100.02% from the prior year.
• Cash from Financing Activities grew to $5000.0 in Q1 2026, from -$21000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $128.4 million in Q2 2024 to a low of -$21000.0 in Q4 2025.
• A 4-year average of $13.2 million and a median of $32500.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 534908.33% — and 2025, when it plunged 151.22%.
• Tracing CLYM's Cash from Financing Activities over 4 years: stood at $288000.0 in 2023, then slumped by 85.76% to $41000.0 in 2024, then sank by 151.22% to -$21000.0 in 2025, then surged by 123.81% to $5000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $5000.0 (Q1 2026), -$21000.0 (Q4 2025), and $41000.0 (Q4 2024), per Business Quant data.